Blog
Getting the word out about clinical trials
Melissa Fassbender, of OutSourcing-Pharma, published an article about a SubjectWell survey on Clinical Trial Awareness and Attitudes. For those surveyed: 50% are not aware of clinical trials and 57% could not recall any advertising for clinical trials. The lack of...
Friday April 8th, Gretchen Bowker speaking for Purdue University at Roche Devices and Diagnostics Course
“Ethics, Quality and Human Safety in Clinical Trials: The Role of the IRB in Medical Device Studies” is the topic of an upcoming lecture by Gretchen Bowker, Pearl Pathways COO and Co-Founder, for Purdue University. The two-day event, April 8-9, is held at Roche and...
Director of Business Development, Pannucci Honored as ICBI Advisory Council Member
Check out the below from our press release issued today: Pearl Pathways’ Director of Business Development, Pannucci one of select group of Indianapolis area life science industry executives to make up the ICBI Advisory Council INDIANAPOLIS, INDIANA – March 23, 2016 -...
Debate over biobank donation compensation – what if your genes lead to a blockbuster drug?
Check out this fascinating article in Fast Company authored by Christina Farr debating ethical issues in how biobank donors should be compensated if their DNA leads to a blockbuster discoveries by big pharma. One of the case studies examined is donors whose rare...
FDA’s COA Compendium — a tool for patient focused drug development
Ed Miseta of Clinical Leader, recently wrote an excellent article about FDA’s pilot Clinical Outcome Assessment (COA) Compendium and hit on some good points about what you need to know about it. The FDA defines a COA as a “measure of a patient’s symptoms, overall...